Stay updated on GO-Gilteritinib Combo in FLT3-ITD AML Clinical Trial
Sign up to get notified when there's something new on the GO-Gilteritinib Combo in FLT3-ITD AML Clinical Trial page.

Latest updates to the GO-Gilteritinib Combo in FLT3-ITD AML Clinical Trial page
- CheckyesterdayChange DetectedThe record now shows Active, not recruiting and an updated title reflecting Relapse/Refractory AML. It also adds new sections including IPDSharing, Contacts/Locations, Study Design, Conditions, Study Description, Oversight, Sponsor/Collaborators, and Recruitment Status.SummaryDifference2%

- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedAdded a new revision entry (Revision: v3.3.3) to the study's Record History. Removed the HHS Vulnerability Disclosure item and Revision: v3.3.2.SummaryDifference0.2%

- Check22 days agoNo Change Detected
- Check36 days agoChange DetectedA new revision entry (v3.3.2) was added. The previous revision (v3.3.1) was removed.SummaryDifference0.1%

- Check43 days agoChange DetectedA new revision entry v3.3.1 was added to the history and the v3.2.0 revision was removed; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check51 days agoChange DetectedThe government funding status notice/banner was removed from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.7%

- Check65 days agoChange DetectedA new version entry appears in the record history, while the main study details appear unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to GO-Gilteritinib Combo in FLT3-ITD AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the GO-Gilteritinib Combo in FLT3-ITD AML Clinical Trial page.